Why the NHS knee surgery queue is pushing patients toward alternatives

For most patients with knee cartilage damage, the NHS pathway to surgical treatment is sequential rather than direct. A GP consultation leads to community MSK assessment, then a physiotherapy programme, and only after those stages is a surgical referral considered — meaning knee replacement or arthroscopy sits at the far end of a multi-step process. NHS England publishes monthly Referral to Treatment (RTT) data covering 2026–27, and orthopaedic elective backlogs remain a documented patient-experience pressure point; current wait figures are available through the NHS England RTT interactive dashboard for anyone researching their own position.

That timeline is appropriate context for where the NHS is, not a criticism of it. Total knee replacement is an irreversible procedure under general anaesthetic that resurfaces the entire joint with metal and polyethylene implants — the clinically correct intervention for end-stage arthritis, but a high threshold that many patients with moderate or focal cartilage damage have not yet reached. For them, entering an orthopaedic waiting list for a procedure they may not yet need creates a practical gap between their symptoms and their options.

Self-funding an outpatient injection pathway closes that gap: no GP referral is required, no RTT queue applies, and a consultant assessment can take place within days rather than months. The rest of this article addresses specifically where ChondroFiller injection fits for patients at that intermediate stage — and where NHS surgery remains the right answer.

What ChondroFiller injection involves as an outpatient appointment

Arriving at the clinic, patients are positioned on a treatment couch rather than an operating table. A consultant applies ultrasound to locate the affected compartment precisely, then introduces the ChondroFiller® collagen scaffold directly into the knee through a single guided injection — the whole appointment typically runs 30 to 45 minutes from arrival to discharge, with no general anaesthetic and no surgical debridement of the joint surface.

Once placed, the acellular Type I collagen solution gels in situ within 3–5 minutes, forming a scaffold that coats the worn cartilage surface. The mechanism is acellular matrix-induced chondrogenesis: the scaffold recruits the patient's own progenitor cells from the synovium and subchondral bone to support the body's repair processes. There is no incision, no theatre admission, and no overnight stay.

After a short observation period, patients leave the clinic the same day, and a phased rehabilitation programme begins within hours of the injection. A six-week follow-up is included in the treatment package.

Two eligibility features are clinically significant. ChondroFiller injection carries no upper age limit and no defect-size exclusion, so patients who may not qualify for joint-preserving surgical techniques on those grounds remain suitable candidates. Access is also straightforward: no GP referral is needed to book.

For patients outside London, MSK Doctors — bookable directly at mskdoctors.com — is the starting point for a consultant assessment. The group's London arm, London Cartilage Clinic at 66 Harley Street, is the current UK site for ChondroFiller injection delivery.

What the clinical evidence shows at 12 months and beyond

Published outcomes data from four knee studies consistently show patient-reported IKDC scores improving by approximately 30 points at 12 months — a meaningful margin above the accepted Minimal Clinically Important Difference of 16.7 points. The IKDC (International Knee Documentation Committee) score is a validated patient-reported measure of knee symptoms, function, and activity, running from 0 to 100; a 30-point shift represents a substantial change in daily life. The prospective Jerosch et al. post-market clinical follow-up study extended this picture to three years, finding that the mean improvement of 32.4 points was sustained and slightly increased, with patients reaching a functional IKDC score of 80 — a level consistent with near-normal knee activity.

Structural repair has been measured independently using MRI-based MOCART scores (Magnetic resonance Observation of Cartilage Repair Tissue), which assess defect filling and integration with surrounding native cartilage on a 0–100 scale. European studies report MOCART scores of 81.6 to 84.3, indicating greater than 80% defect filling. Scores improved from 65.3 at four weeks to 81.6 at one year, which aligns with the biological timeline: the scaffold is progressively replaced by the patient's own tissue over 12 months, with full resorption by one to two years.

Current data comes from manufacturer-sponsored studies and European registries; UK-specific independent RCT data for the injectable formulation is not yet available. For a CE-marked Class III device within an active post-market clinical follow-up programme, that is a normal position — not a safety concern — but it is an honest limitation worth noting when weighing the evidence.

Which patients are most likely to benefit

The typical candidate has already tried physiotherapy without adequate relief and carries MRI-confirmed Grade III or IV cartilage damage that is not yet bone-on-bone throughout the joint. End-stage osteoarthritis — where the articular surface is substantially lost and pain is driven by bone-on-bone contact — remains outside the scope of injectable scaffold therapy; total knee replacement addresses that presentation more reliably.

Within that boundary, the eligible population is notably broad. Younger, active patients often seek ChondroFiller to preserve the joint and defer or avoid replacement — a clinically understandable priority given that a knee implant carries a finite lifespan and the possibility of revision surgery further down the line. Older patients who are not suitable for, or prefer to avoid, a general anaesthetic also fall comfortably within scope.

A more specific contrast is with joint-preserving surgical techniques such as OATS (osteochondral autograft transfer) or ACI (autologous chondrocyte implantation). Those procedures perform best on contained, focal defects within defined size parameters and are typically restricted to younger patients with structurally intact surrounding tissue. The injectable scaffold route does not impose equivalent constraints; it can address more diffuse or multi-compartment wear patterns that would fall outside the eligibility window for those techniques.

Individual suitability depends on the full clinical picture — imaging, symptom history, and biomechanical factors — and is properly established through a consultant assessment. MSK Doctors can be booked directly, without a GP referral, at mskdoctors.com.

Cost and access compared to the surgical pathway

ChondroFiller injection is entirely self-funded. It is not available on the NHS and is not currently covered by private medical insurance, so the full cost sits with the patient from the outset.

The practical upside of that arrangement is direct access: no GP referral, no community MSK triage, no RTT queue. Patients book a consultant appointment and, where ChondroFiller is appropriate, can proceed to treatment without the sequential NHS pathway described in the opening section.

On guide cost, published figures for the injectable pathway start from around £3,000 for a single-box treatment — inclusive of consultation, ultrasound guidance, the product, and a six-week follow-up appointment. Larger or multi-compartment presentations may require two or three boxes, so confirmed pricing for any individual patient is best established at consultation. For context, a private keyhole surgical cartilage repair procedure under general anaesthetic typically runs to significantly higher sums — the gap between an outpatient injection pathway and a private surgical one is substantial.

NHS total knee replacement costs the patient nothing at the point of use. The trade-off is the full RTT pathway — a multi-stage journey from GP to community MSK services to surgical referral — alongside inpatient admission, general anaesthetic risk, and a considerably longer rehabilitation arc. For patients weighing immediate self-funded access against a free but deferred surgical route, that contrast is the central financial and logistical decision to resolve.

Weighing the injection route against waiting for surgery

The two pathways do not compete on the same clinical ground. ChondroFiller injection addresses moderate cartilage damage where the joint still has structural tissue worth preserving; total knee replacement addresses end-stage disease where that tissue is substantially exhausted. Choosing between them is therefore not simply a question of preference or cost — it depends on where a patient sits on the disease-severity spectrum, and that requires objective clinical assessment rather than self-diagnosis.

For patients with MRI-confirmed moderate damage who have not reached bone-on-bone contact throughout the joint, the injectable scaffold route offers a clinically evidenced option that can be accessed immediately, without surgical risk or a prolonged waiting period. A consultant can map the degree of damage and establish whether that profile fits the ChondroFiller pathway, or whether a different approach — including surgical options — is the better match.

MSK Doctors accepts patients directly, without GP referral, with consultant-led assessments available across Lincolnshire and the wider region. Details and appointments are at mskdoctors.com.

1. [1] Knee replacement - NHS. https://www.nhs.uk/conditions/knee-replacement/ https://www.nhs.uk/conditions/knee-replacement/